Samuel J Burton1, Christine Hachem1, James M Abraham2. 1. Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MI, USA. 2. Department of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. jamabrah@med.umich.edu.
Abstract
PURPOSE OF REVIEW: People with cystic fibrosis (CF) are living longer. General age-related and CF-specific gastrointestinal symptoms are increasingly recognized. In this article, we review the latest data on luminal gastrointestinal manifestations in CF. RECENT FINDINGS: People with CF have increased incidence of gastroesophageal reflux disease symptoms and often prescribed proton-pump inhibitors (PPI). PPI use may increase risk of pulmonary exacerbations. Evidence to support gastric fundoplication to improve pulmonary outcomes is limited. Features of intestinal dysmotility are common. There are distinct differences in the gut microbiome in the CF population which may have clinical implications. CF is a possible hereditary digestive cancer syndrome, particularly in regard to colorectal cancer (CRC) with earlier incidence of CRC and advanced colonic neoplasia. Early screening colonoscopy is warranted in the CF population. Gastrointestinal manifestations in CF are prevalent across all digestive organs. More study on the effect of interventions for symptomatic treatment and cancer screening is needed.
PURPOSE OF REVIEW: People with cystic fibrosis (CF) are living longer. General age-related and CF-specific gastrointestinal symptoms are increasingly recognized. In this article, we review the latest data on luminal gastrointestinal manifestations in CF. RECENT FINDINGS:People with CF have increased incidence of gastroesophageal reflux disease symptoms and often prescribed proton-pump inhibitors (PPI). PPI use may increase risk of pulmonary exacerbations. Evidence to support gastric fundoplication to improve pulmonary outcomes is limited. Features of intestinal dysmotility are common. There are distinct differences in the gut microbiome in the CF population which may have clinical implications. CF is a possible hereditary digestive cancer syndrome, particularly in regard to colorectal cancer (CRC) with earlier incidence of CRC and advanced colonic neoplasia. Early screening colonoscopy is warranted in the CF population. Gastrointestinal manifestations in CF are prevalent across all digestive organs. More study on the effect of interventions for symptomatic treatment and cancer screening is needed.
Authors: Brenda M Button; Stuart Roberts; Tom C Kotsimbos; Bronwyn J Levvey; Trevor J Williams; Michael Bailey; Gregory I Snell; John W Wilson Journal: J Heart Lung Transplant Date: 2005-10 Impact factor: 10.247
Authors: J Navarro; M Rainisio; H K Harms; M E Hodson; C Koch; G Mastella; B Strandvik; S G McKenzie Journal: Eur Respir J Date: 2001-08 Impact factor: 16.671
Authors: Todd MacKenzie; Alex H Gifford; Kathryn A Sabadosa; Hebe B Quinton; Emily A Knapp; Christopher H Goss; Bruce C Marshall Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: K Blondeau; L J Dupont; V Mertens; G Verleden; A Malfroot; Y Vandenplas; B Hauser; D Sifrim Journal: Gut Date: 2008-03-27 Impact factor: 23.059
Authors: Hubert P J van der Doef; Hubertus G M Arets; Steven P Froeling; Paul Westers; Roderick H J Houwen Journal: J Pediatr Date: 2009-08-14 Impact factor: 4.406
Authors: Jochen G Mainz; Carlos Zagoya; Louise Polte; Lutz Naehrlich; Lenny Sasse; Olaf Eickmeier; Christina Smaczny; Anton Barucha; Lilith Bechinger; Franziska Duckstein; Ludwik Kurzidim; Patience Eschenhagen; Laura Caley; Daniel Peckham; Carsten Schwarz Journal: Front Pharmacol Date: 2022-06-03 Impact factor: 5.988